- Home
- RARE vs KNSA Comparison
RARE vs KNSA Comparison
Compare RARE & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | KNSA |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RARE | KNSA |
|---|---|---|
| Price | $34.86 | $43.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $85.20 | $51.33 |
| AVG Volume (30 Days) | ★ 1.5M | 399.9K |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | ★ $630,598,000.00 | $597,973,000.00 |
| Revenue This Year | $19.09 | $62.63 |
| Revenue Next Year | $20.62 | $29.93 |
| P/E Ratio | ★ N/A | $92.52 |
| Revenue Growth | 20.63 | ★ 55.68 |
| 52 Week Low | $25.81 | $17.82 |
| 52 Week High | $46.50 | $43.73 |
Technical Indicators
Market Signals| Indicator | RARE | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 67.33 |
| Support Level | $32.64 | $40.77 |
| Resistance Level | $36.81 | $42.32 |
| Average True Range (ATR) | 1.60 | 1.45 |
| MACD | -0.29 | 0.12 |
| Stochastic Oscillator | 28.83 | 81.29 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.